Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Renal Cell 7Sarcoma 5Melanoma 5Lymphoma, Non-Hodgkin 5Prostatic Neoplasms 4Ovarian Neoplasms 4Neoplasms 4Endometrial Neoplasms 4Carcinoma, Hepatocellular 4Neoplasm Metastasis 3Multiple Myeloma 3Lymphoma, Large B-Cell, Diffuse 3Leukemia, Myeloid, Acute 3Kidney Neoplasms 3Glioblastoma 3Squamous Cell Carcinoma of Head and Neck 2Rhabdomyosarcoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Lymphoma, Mantle-Cell 2Liver Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2Fallopian Tube Neoplasms 2Congenital Abnormalities 2Breast Neoplasms 2Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1

Interventions

Cisplatin 39Radiotherapy 21Carboplatin 21Cetuximab 20Paclitaxel 19Docetaxel 17Radiotherapy, Intensity-Modulated 15pembrolizumab 14Fluorouracil 13Drug Therapy 10Nivolumab 8Radiation 6cemiplimab 5atezolizumab 5Panitumumab 5Oxaliplatin 5Erlotinib Hydrochloride 5Chemoradiotherapy 5Afatinib 5Surgical Procedures, Operative 4durvalumab 3Surveys and Questionnaires 3Methotrexate 3Leucovorin 3Lapatinib 3130-nm albumin-bound paclitaxel 3toripalimab 2palbociclib 2osimertinib 2dacomitinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Squamous Cell × temsirolimus × Clear all
NCT01009203 2015-08-10

Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell Carcinoma

New Mexico Cancer Research Alliance

Phase 2 Terminated
13 enrolled 8 charts
Tumor-Agnostic

Carcinoma, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡